Whilst blockade of the PD-L1 signal with an anti-PD-1 antibody clearly sensitized TRAMP-C2 tumours to cytotoxic T lymphocyte (CTL) killing in the current study, results will be presented to show whether blockade of BTLA can synergise with anti-PD-1 at reversing tumour-specific T cell inhibition. Here, PDCD1 is linked to neoplasm.